Skip to content
Open in App
Acrivon Therapeutics logo

Acrivon Therapeutics

web2

Acrivon Therapeutics is an American clinical stage biotechnology company developing precision o...

Symbol ยท ACRV
Company profile

About

Acrivon Therapeutics is an American clinical stage biotechnology company developing precision oncology medicines and diagnostic tests intended to identify patients likely to benefit from specific cancer treatments. Its proprietary AP3 platform analyzes protein signaling activity to investigate tumor biology and support drug development and patient selection. The lead candidate, ACR368, also known as prexasertib, inhibits checkpoint kinases involved in cellular responses to DNA damage and is being evaluated in clinical trials. Acrivon also develops ACR2316, targeting the WEE1 and PKMYT1 kinases, and the investigational CDK11 inhibitor ACR7280. Its therapeutic programs remain subject to clinical development and regulatory evaluation.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ACRV
Expert coverage

Acrivon Therapeutics profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment